{"entity":{"id":"nct06389292","kind":"trial","name":"A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia","aka":["GLORA-3"],"tldr":"A phase 3 trial of Azacitidine in acute myeloid leukaemia, run by Ascentage Pharma Group Inc., now recruiting.","summary":"A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia is a phase 3 interventional study registered as NCT06389292 by Ascentage Pharma Group Inc., with 486 participants planned, started 2024-06-11 and due to reach its primary completion in 2028-05-25. Interventions recorded: APG-2575(Lisaftoclax ) and Azacitidine Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06389292","url":"https://clinicaltrials.gov/study/NCT06389292"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","aml-older-unfit"],"sections":[],"technologies":["cytotoxic-chemotherapy","epigenetic-drugs"],"targets":[],"drugs":["azacitidine"],"companies":["ascentage-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06389292","phase":"3","setting":"A Global, Multicenter, Randomized, Double-blind, Phase 3 Pivotal Registrational Clinical Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (GLORA-3)","sponsor":"Ascentage Pharma Group Inc.","started":"2024-06-11","startedType":"actual","enrolled":486,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06389292/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"}],"company":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/"}]}}